Mixed Monoclonal Antibody Cocktail for Cancer Therapy from China
A blended preparation of multiple monoclonal antibodies (MABs) such as trastuzumab and pertuzumab for targeted cancer immunotherapy. Classified under HTS 3002.14.00 as mixed immunological products not in measured doses or retail packaging, involving peptides and proteins regulating immunological processes.
Duty Rate — China → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Verify product is mixed (e.g
• multiple MABs combined) and not in measured doses via Certificate of Analysis to confirm 3002.14.00
• Provide biotech process documentation and immunological activity proof; avoid retail packing to prevent reclassification